CyMedica Orthopedics announced that the Food and Drug Administration (FDA) has granted clearance for e-vive, an app-controlled, data-driven muscle activation therapy and patient engagement solution.
The first-of-its-kind system is intended to drive at-home pre-hab to rehab muscle strengthening for ACL and total knee replacement patients. The e-vive wireless muscle stimulation device addresses the issues associated with muscle atrophy experienced by patients who undergo knee surgery. The patient can use the device to improve quadriceps function while the clinician monitors his or her rehabilitation progress.
The e-vive app can be used on virtually any smartphone with embedded garment sensor technology that sends key data such as range of motion, activity levels, and pain scores, to a secure cloud based portal. Through this, clinicians can monitor patient progress and self-reported measures to offer more predictable outcomes.
For more information visit CyMedicaortho.com.